Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. STIM
stocks logo

STIM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
40.66M
+83.99%
-0.110
+161.47%
37.22M
+16.4%
-0.130
-38.1%
41.79M
+9.67%
-0.120
-20%
Estimates Revision
The market is revising Downward the revenue expectations for Neuronetics, Inc. (STIM) for FY2025, with the revenue forecasts being adjusted by -1.46% over the past three months. During the same period, the stock price has changed by -55.11%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.46%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.64%
In Past 3 Month
Stock Price
Go Down
down Image
-55.11%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Neuronetics Inc (STIM.O) is -3.02, compared to its 5-year average forward P/E of -5.57. For a more detailed relative valuation and DCF analysis to assess Neuronetics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.57
Current PE
-3.02
Overvalued PE
-0.42
Undervalued PE
-10.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-14.31
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.79
Undervalued EV/EBITDA
-37.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.90
Current PS
0.00
Overvalued PS
3.57
Undervalued PS
0.23
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 8387.81% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 8387.81% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

STIM News & Events

Events Timeline

(ET)
2025-11-04
07:26:08
Neuronetics projects FY25 revenue between $147M and $150M, below consensus estimate of $151.03M.
select
2025-11-04
07:24:50
Neuronetics CEO Keith Sullivan Announces Retirement
select
2025-11-04
07:24:18
Neuronetics Announces Q3 Earnings Per Share: 13 Cents Compared to Last Year's 44 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
11-18Benzinga
Three Health Care Stocks That Could Revitalize Your Portfolio This November

  • Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.

  • Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.

  • Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.

  • Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.

[object Object]
Preview
9.0
11-12Newsfilter
TRICARE West Broadens NeuroStar® TMS Coverage to Support Adolescents 15 and Older Facing Depression

  • TRICARE Coverage Expansion: Neuronetics, Inc. announced that TriWest has updated its medical policy to include TMS coverage for adolescents aged 15 and older, benefiting military families in multiple states.

  • Significance of TMS for Adolescents: The expansion of TMS coverage is seen as a crucial step in providing effective treatment for adolescents struggling with depression, especially given the limited medication options available.

  • NeuroStar's Unique Position: NeuroStar is the first TMS company with FDA clearance for adolescent treatment and has a dedicated health policy team advocating for further access to TMS therapy.

  • Impact on Mental Health: With an estimated 4.3 million U.S. adolescents affected by major depression, NeuroStar Advanced Therapy offers a non-invasive treatment option that can significantly improve quality of life when traditional medications fail.

[object Object]
Preview
9.5
11-04Newsfilter
Neuronetics Releases Financial and Operational Results for Q3 2025 and Unveils CEO Transition Strategy

  • Financial Performance: Neuronetics reported Q3 2025 revenue of $37.3 million, an 11% increase on an adjusted pro forma basis compared to Q3 2024, with significant growth in Greenbrook clinic revenue, which reached $21.8 million, a 25% increase year-over-year.

  • Operational Highlights: The company achieved over 229,429 global patients treated and received $10 million in additional funding under a debt agreement, while New York State Medicaid expanded coverage for TMS therapy, enhancing access for over 5 million members.

  • Leadership Transition: CEO Keith J. Sullivan announced his intention to retire on June 30, 2026, after five years of leadership, during which he played a key role in the strategic acquisition of Greenbrook TMS.

  • Future Outlook: Neuronetics anticipates Q4 2025 revenue between $40 million and $43 million, with a target for positive cash flow from operations, while adjusting full-year revenue expectations to between $147 million and $150 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Neuronetics Inc (STIM) stock price today?

The current price of STIM is 1.45 USD — it has increased 8.21 % in the last trading day.

arrow icon

What is Neuronetics Inc (STIM)'s business?

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.

arrow icon

What is the price predicton of STIM Stock?

Wall Street analysts forecast STIM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for STIM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Neuronetics Inc (STIM)'s revenue for the last quarter?

Neuronetics Inc revenue for the last quarter amounts to 37.30M USD, increased 101.28 % YoY.

arrow icon

What is Neuronetics Inc (STIM)'s earnings per share (EPS) for the last quarter?

Neuronetics Inc. EPS for the last quarter amounts to -0.13 USD, decreased -70.45 % YoY.

arrow icon

What changes have occurred in the market's expectations for Neuronetics Inc (STIM)'s fundamentals?

The market is revising Downward the revenue expectations for Neuronetics, Inc. (STIM) for FY2025, with the revenue forecasts being adjusted by -1.46% over the past three months. During the same period, the stock price has changed by -55.11%.
arrow icon

How many employees does Neuronetics Inc (STIM). have?

Neuronetics Inc (STIM) has 716 emplpoyees as of December 05 2025.

arrow icon

What is Neuronetics Inc (STIM) market cap?

Today STIM has the market capitalization of 91.77M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free